Key facts
- This page summarizes Watson David O's Form 4 filing for Apellis Pharmaceuticals, Inc. (APLS).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 23 Jun 2022, 16:22.
Watson David O - 22 Jun 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)
- Reporting relationship
- General Counsel
- Issuer ticker
- APLS
- Reported as of
- 22 Jun 2022
- Net transaction value
- -$445,140
- SEC form
- 4
- Accepted by SEC
- 23 Jun 2022, 16:22:34 UTC
- Prior SEC filing
- 27 Apr 2022
- Next SEC filing
- 17 Jan 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ David Watson
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Watson David O filed Form 4 for Apellis Pharmaceuticals, Inc. (APLS) on 23 Jun 2022.
Change
- Previous filing in this sequence was filed on 27 Apr 2022.
- Current net transaction value: -$445,140.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
APLS
transaction
Common Stock
Sale
- Transaction value
- $445,140
- Shares
- -10,000
- Change %
- -8%
- Price
- $44.51
- Shares after
- 115,569
- Date
- 22 Jun 2022
- Ownership
- Direct
- Footnotes
- F1
APLS
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 3,333
- Date
- 22 Jun 2022
- Ownership
- Indirect Owner (Custodial Account for Son)
- Footnotes
- F2
APLS
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 6,667
- Date
- 22 Jun 2022
- Ownership
- Indirect Owner (The Watson Education Trust)
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
These shares were sold in multiple transactions at prices ranging from $44.50 to $44.635, inclusive. The reporting person undertakes to provide to Apellis Pharmaceuticals, Inc., any security holder of Apellis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4.
Footnote F2
This represents a custodial account held by the reporting person for the sole benefit of his minor son.
Footnote F3
The securities are held by The Watson Education Trust (the "Trust"), for which the reporting person serves as trustee. The reporting person disclaims beneficial ownership over the shares held by the Trust except to the extent of his pecuniary interest therein.